All news

Wells Fargo lifts REGN target to $925 on execution

Alpha Vantage · Investing.com · · AI-summarised by FinFlash

Wells Fargo has increased its price target for Regeneron Pharmaceuticals (NASDAQ: REGN) shares to $925 from $750, maintaining an "Equal Weight" rating, citing strong commercial execution. The stock is currently trading near its 52-week high after a recent surge. The firm projects $83 per share in 2027 earnings, with potential for further multiple expansion as valuation is considered reasonable.

Read original source

REGN company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.